CUDC-101 (120 mg/kg) causes significant tumor regression in the lapatinib-resistant, HER2-negative, EGFR-overexpressing MDA-MB-468 breast cancer model and the EGFR-overexpressing CAL-27 head and neck squamous cell carcinoma (HNSCC) model. CUDC-101 (120 mg/kg) also inhibits tumor growth in ...
gastric, breast, liver and non-small cell lung cancer tumors. How to Use: In vitro:CUDC-101 was used at 1 µM final concentration in vitro and in cellular assays. In vivo:CUDC-101 was IP or IV dosed to mice at 120 mg/kg once per day in the xenograft tumor model of Hep-G2, ...
Discontinued Breast cancer; Gastric cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Solid tumours Most Recent Events 01 Jun 2014 Curis terminates a phase I clinical trials in Solid tumours (late-stage disease) in USA (NCT01702285) 30 Nov 2012 Curis terminates a ...
(SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib. [2]In vivo, CUDC-101 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers...
[2]In vivo, CUDC-101 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers. [2]br /[1] Cai X et al. J Med Chem. 2010 Mar 11;53(5):2000-9 ...
[2] Lai C J, Bao R, Tao X U, et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer research, 2010, 70(9): 3647-3656. ...
In vivo, CUDC-101 promoted tumor regression in various cancer xenograft models such as non-small cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers. Cai, X., et al. "Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxy...
CUDC-101是一种有效的,多靶点抑制剂,作用于HDAC,EGFR和HER2,IC50分别为4.4 nM, 2.4 nM,和15.7 nM,且抑制I/II型HDACs,但是对III型, Sir-type HDACs没有抑制作用。Phase 1。 CUDC-101 Chemical Structure CAS: 1012054-59-9 规格价格库存购买数量 ...
Radiosensitization Effects of Novel Triple-Inhibitor CUDC-101 in Glioblastoma Multiforme and Breast Cancer Cells In VitroConnectome matrixdiffusion tensor imagingelectroencephalographyinverse problemsneuroimagingThe electroencephalography source estimation problem consists of inferring cortical activation from ...